Pfizer, in the context of "a review relating to its research sector worldwide, announces that it intends to sell the Toxicology Center of Catania".
This was reported in a note which indicates that "negotiations are underway to transfer the site to qualified third parties. This decision has no impact on the production plant, which employs a total of 750 people and was confirmed last May as a consolidated site for sterile production within Pfizer's production network. Aware of the high relevance of the Toxicology Center and in order to preserve its value and human heritage, Pfizer considered all scenarios. Among them, the transfer of the site to a qualified counterparty was identified as the best solution.Pfizer has therefore opened an ongoing dialogue with all the authorities and has begun to evaluate a significant number of potential partners, able to ensure the future of the center and maintain its employment.
The contractual agreements relating to the Public-Private Laboratory - Pfizer specifies in particular, referring to the structure that employs 77 researchers - will be maintained and carried forward until their completion and all the obligations deriving from the existing agreements will be fully respected".
PharmaKronos – February 2, 2011
02/02/2011
Time of crisis: Pfizer leaves Catania
It's the crisis, honey. In Catania, another company throws in the towel. The American pharmaceutical giant Pfizer Inc. he made it known yesterday in a statement that he will sell his own Etna plant, in which 750 employees work.
The transfer of the Catania toxicology center to another interested party was decided by the New York company after a review of its research sector worldwide. Pfizer did a couple of maths and found
